Goodwin advised Scholar Rock on the deal
Scholar Rock as it closed a $47 million Series C financing round to advance SRK-015, the company’s lead clinical candidate for Spinal Muscular Atrophy (SMA) and other neuromuscular disorders. The financing was led by new investor Invus, with the participation of new investor Redmile Group. All of the existing investors in Scholar Rock also participated in this financing round, including Polaris Partners, Timothy Springer, ARCH Venture Partners, EcoR1 Capital, The Kraft Group, Fidelity Management and Research Company, and Cormorant Asset Management.
Scholar Rock is discovering and developing a pipeline of innovative new medicines to treat a range of serious diseases in which growth factors play a fundamental role, including neuromuscular diseases, cancer and fibrosis. The company, led by Nagesh K. Mahanthappa, Timothy A. Springer, Leonard I. Zon, Elan Z. Ezickson and Yung H. Chyung, is based in Cambridge.
The Goodwin team was led by partner Laurie Burlingame (Picture) and included partners Kingsley Taft and Daniel Karelitz.
Law Firms: Goodwin Procter;
Clients: Scholar Rock Inc.;